Altered cerebrovascular proteome in Alzheimer’s disease mice and the effect of pharmacotherapy

AuthorSearch for:
ConferencePromoting Healthy Brain Aging and Preventing Dementia: Research and Translation, 24–27 May 2016, Banff, Canada
AbstractCerebrovascular insufficiency appears years prior to clinical symptoms in Alzheimer’s disease (AD). The soluble, highly toxic amyloid-beta (Aβ) species, generated from the amyloidogenic processing of amyloid precursor protein (APP), are known instigators of the chronic cerebrovascular hypoperfusion observed in AD patients. To date, the global response of the cerebrovascular proteome to excess soluble Aβ and to pharmacotherapy that normalizes cerebrovascular function remains poorly understood. We previously demonstrated that the anti-diabetic drug pioglitazone, currently in a Phase III trial for delay of AD onset, reverses cerebrovascular impairment in a mouse model of AD overexpressing Aβ (APP mice). In this study, we characterized the effects of soluble Aβ overproduction on the cerebrovascular proteome of mice; determined how pioglitazone-treatment affected the altered proteome; and analyzed the relationship between normalized protein levels and recovery of cerebrovascular function.
Publication date
AffiliationNRC Institute for Biological Sciences; National Research Council Canada
Peer reviewedNo
NPARC number23000444
Export citationExport as RIS
Report a correctionReport a correction
Record identifier25437019-3624-48b1-81b1-07b9b80e9e57
Record created2016-07-19
Record modified2016-07-19
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)
Date modified: